Tessa I van Rijssel, Ghislaine J M W van Thiel, Helga Gardarsdottir, Johannes J M van Delden
{"title":"Which Benefits Can Justify Risks in Research?","authors":"Tessa I van Rijssel, Ghislaine J M W van Thiel, Helga Gardarsdottir, Johannes J M van Delden","doi":"10.1080/15265161.2023.2296404","DOIUrl":null,"url":null,"abstract":"<p><p>Research ethics committees (RECs) evaluate whether the risk-benefit ratio of a study is acceptable. Decentralized clinical trials (DCTs) are a novel approach for conducting clinical trials that potentially bring important benefits for research, including several collateral benefits. The position of collateral benefits in risk-benefit assessments is currently unclear. DCTs raise therefore questions about how these benefits should be assessed. This paper aims to reconsider the different types of research benefits, and their position in risk-benefit assessments. We first propose a categorization of research benefits, based on the types of benefits that can be distinguished from the literature and ethical guidelines. Secondly, we will reconsider the position of collateral benefits. We argue that these benefits are not fundamentally different from other benefits of research and can therefore be included in risk-benefit assessments of DCTs.</p>","PeriodicalId":50962,"journal":{"name":"American Journal of Bioethics","volume":" ","pages":"65-75"},"PeriodicalIF":17.0000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Bioethics","FirstCategoryId":"98","ListUrlMain":"https://doi.org/10.1080/15265161.2023.2296404","RegionNum":1,"RegionCategory":"哲学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/5 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ETHICS","Score":null,"Total":0}
引用次数: 0
Abstract
Research ethics committees (RECs) evaluate whether the risk-benefit ratio of a study is acceptable. Decentralized clinical trials (DCTs) are a novel approach for conducting clinical trials that potentially bring important benefits for research, including several collateral benefits. The position of collateral benefits in risk-benefit assessments is currently unclear. DCTs raise therefore questions about how these benefits should be assessed. This paper aims to reconsider the different types of research benefits, and their position in risk-benefit assessments. We first propose a categorization of research benefits, based on the types of benefits that can be distinguished from the literature and ethical guidelines. Secondly, we will reconsider the position of collateral benefits. We argue that these benefits are not fundamentally different from other benefits of research and can therefore be included in risk-benefit assessments of DCTs.
期刊介绍：
The American Journal of Bioethics (AJOB) is a renowned global publication focused on bioethics. It tackles pressing ethical challenges in the realm of health sciences.
With a commitment to the original vision of bioethics, AJOB explores the social consequences of advancements in biomedicine. It sparks meaningful discussions that have proved invaluable to a wide range of professionals, including judges, senators, journalists, scholars, and educators.
AJOB covers various areas of interest, such as the ethical implications of clinical research, ensuring access to healthcare services, and the responsible handling of medical records and data.
The journal welcomes contributions in the form of target articles presenting original research, open peer commentaries facilitating a dialogue, book reviews, and responses to open peer commentaries.
By presenting insightful and authoritative content, AJOB continues to shape the field of bioethics and engage diverse stakeholders in crucial conversations about the intersection of medicine, ethics, and society.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
